GHK-Cu is a naturally occurring copper peptide that has become increasingly popular in conversations about skin health, healthy aging, tissue repair and peptide therapy.
You may already recognize it as an ingredient in copper peptide skincare products. It is also available through some healthcare providers as a compounded injectable treatment. While these forms use the same peptide, they work differently and are supported by different types of research.
Here’s what we currently know about GHK-Cu, why it continues to interest researchers and clinicians, and what to expect if you are considering treatment.
What Is GHK-Cu?
GHK-Cu is created when a small peptide called GHK binds to copper. GHK is made from three amino acids: glycine, histidine and lysine.
Both GHK and copper occur naturally in the body. Copper contributes to several important functions, including collagen formation, connective-tissue support, energy production and antioxidant activity.
GHK appears to help bind and carry copper while also participating in the signals cells use to maintain and repair tissue. This combination is what makes GHK-Cu particularly interesting in skincare, regenerative wellness and healthy-aging research.
Natural GHK levels appear to decrease as we age. Researchers are exploring whether that decline may be connected to age-related changes in skin structure and the body’s repair processes.
The History of GHK-Cu
GHK was first identified in 1973 during research comparing younger and older human tissue. Scientists discovered that a small substance found in younger blood plasma appeared to influence the activity of older cells.
That substance was eventually identified as GHK. Researchers later found that it binds strongly to copper, forming the compound now known as GHK-Cu.
In the decades since, GHK-Cu has been studied for its possible involvement in:
- Collagen and elastin production
- Skin firmness and texture
- Tissue remodeling
- Wound repair
- Inflammatory and antioxidant activity
- Hair-follicle support
- Cellular communication
- Healthy aging
Its long research history and natural presence in the body have helped distinguish GHK-Cu from many newer peptides.
How Does GHK-Cu Work?
GHK-Cu appears to influence several connected processes rather than producing one isolated effect.
Collagen and Skin Structure
Fibroblasts are cells that create collagen, elastin and other materials that give skin and connective tissue their structure.
Laboratory research suggests that GHK-Cu may support fibroblast activity and influence how tissue is built, broken down and renewed. This is one reason copper peptides are frequently used in products designed to support firmer, smoother-looking skin.
Tissue-Repair Signaling
GHK-containing fragments may be released naturally when tissue is damaged. Researchers believe these fragments may serve as signals that help organize parts of the body’s repair response.
Studies have explored GHK-Cu’s relationship with cell movement, new blood-vessel formation and extracellular-matrix remodeling—the process through which the body removes damaged structural material and replaces it with new tissue.
Antioxidant and Inflammatory Activity
GHK-Cu has also demonstrated antioxidant and anti-inflammatory activity in experimental research. These properties may help support a cellular environment that is more favorable to maintenance and repair.
Researchers are continuing to study how these effects may apply to skin health, recovery and age-related changes.
Gene Activity
Some research suggests that GHK may influence the activity of genes associated with inflammation, cellular maintenance and tissue repair.
This refers to how cells use their existing genetic instructions. Researchers are interested in whether these changes help explain the peptide’s wide range of observed biological activity.
What Does the Research Say About GHK-Cu?
GHK-Cu has been evaluated through laboratory experiments, animal models, topical studies and limited human research. Each category provides a different piece of the overall picture.
Laboratory Research
A large portion of what we know about GHK-Cu comes from cell and tissue studies.
These experiments have connected GHK-Cu with collagen production, fibroblast activity, tissue remodeling, antioxidant defenses, cell migration and inflammatory signaling.
Laboratory research is especially useful for understanding how a compound may work and identifying the applications worth studying further.
Animal Research
Animal studies have examined GHK-Cu in connection with wound healing, nerve recovery and tissue repair. Some of these studies have reported encouraging changes in healing-related measurements and biological markers.
These findings have helped shape continued interest in GHK-Cu, particularly within regenerative and recovery-focused research.
Topical and Cosmetic Research
Topical GHK-Cu has the longest history of consumer use. In skincare products, it commonly appears on ingredient labels as copper tripeptide-1.
Studies have explored its potential effects on:
- Skin firmness
- Elasticity
- Fine lines
- Skin texture
- Collagen-related markers
- Topical wound support
Results vary by product and study design, but the existing research has helped make copper peptides a well-established category in advanced skincare.
How well a topical product performs can depend on the concentration, supporting ingredients, stability of the formula and ability of the peptide to move through the skin barrier.
Human Research
Most published human research has focused on topical skincare or wound-care applications. Injectable GHK-Cu has not been studied in large human clinical trials to the same extent.
As interest in compounded peptide therapy grows, future research may provide clearer information about injectable dosing, treatment duration, potential benefits and longer-term use.
For now, injectable treatment protocols are determined by licensed healthcare providers based on each patient’s health history, goals and clinical evaluation.
Is GHK-Cu FDA-Approved?
As of August 2026, GHK-Cu is not an FDA-approved medication, but its regulatory review is continuing.
In May 2026, the FDA returned GHK-Cu for non-injectable use to Category 1, which includes bulk substances currently under evaluation for use in compounding. The FDA has also announced plans to bring GHK-Cu before its Pharmacy Compounding Advisory Committee by February 2027 to consider its potential inclusion on the 503A Bulks List.
Injectable GHK-Cu is being evaluated separately. The upcoming committee review represents an important next step and could help establish a clearer regulatory path for compounded GHK-Cu as additional research and clinical experience become available.
More information is available through the FDA’s current list of bulk substances under evaluation.
What Does Compounded GHK-Cu Mean?
A compounded medication is prepared by a licensed pharmacy or qualified compounding facility based on a healthcare provider’s prescription. Unlike mass-produced medications, compounded treatments can be prepared in specific strengths or formulations based on an individual patient’s needs.
Why Are Clinicians and Researchers Interested in GHK-Cu?
GHK-Cu sits at the intersection of several areas that matter in regenerative wellness: collagen production, copper regulation, skin structure, cellular signaling, antioxidant activity and tissue repair.
Interest in the peptide continues because it:
- Occurs naturally in the human body
- Has been studied for more than 50 years
- Has well-documented copper-binding properties
- Influences several repair-related pathways in experimental research
- Has an established history in topical skincare
- May have applications extending beyond cosmetic use
Researchers are continuing to investigate how these biological properties may translate into useful human applications. Clinicians are also exploring how compounded GHK-Cu may fit into individualized wellness and peptide-therapy plans.
GHK-Cu Therapy at RegenMD Wellness
RegenMD Wellness offers compounded GHK-Cu therapy to eligible patients following consultation with a licensed healthcare provider.
During the consultation process, the provider reviews factors such as:
- Medical history
- Current medications and supplements
- Wellness goals
- Previous treatments
- Allergies and potential risk factors
- Treatment preferences
- Appropriate monitoring
If GHK-Cu is considered appropriate, the provider develops an individualized prescription and establishes the dose, schedule, treatment length and follow-up plan.
Eligibility is determined through the clinical evaluation, and completing a consultation does not guarantee that GHK-Cu will be prescribed. Patients who begin treatment should follow their provider’s instructions and communicate any side effects, health changes or questions throughout the process.
This article is provided for general educational purposes and does not constitute medical advice. Research discussed may include laboratory, animal, and human studies. Patients should always consult a licensed clinician when considering peptide therapy.
Sources
- Pickart L, Thaler MM. “A Tripeptide in Human Serum Which Prolongs Survival of Normal Liver Cells and Stimulates Growth in Neoplastic Liver.” Nature. 1973.
- Pickart L, Margolina A. “The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging.” Oxidative Medicine and Cellular Longevity. 2012.
- Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Research International. 2015.
- Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences. 2018.
- Mortazavi SM, Moghimi HR. “Topically Applied GHK as an Anti-Wrinkle Peptide: Advantages, Problems and Prospective.” BioImpacts. 2024.
- Mulder GD, et al. “Enhanced Healing of Ulcers in Patients With Diabetes by Topical Treatment With Glycyl-L-Histidyl-L-Lysine Copper.” Wound Repair and Regeneration. 1994.
- Miller TR, et al. “Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin.” Archives of Facial Plastic Surgery. 2006.
- U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.”
- U.S. Food and Drug Administration. “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A.” Updated May 14, 2026.
- U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.”
